3 results
Approved WMOCompleted
To evaluate the effects on ovarian function with the NOMAC/E2 COC in a group of women aged 18-35 years.
Approved WMOCompleted
• To assess contraceptive efficacy, vaginal bleeding patterns (cycle control),general safety and acceptability of the NOMAC-E2 COC in a large group ofwomen aged 18-50 years.
Approved WMOPending
Primary Objective• Evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to standard immunochemotherapy Secondary Objectives• Further evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to…